- New Results Demonstrate Robust Anti-Tumor Activity in Multiple Models, Including Extra-Hepatic Tumors -

- Update on Pipeline Includes New Pre-clinical In Vivo Data Demonstrating that ALN-TTR Blocks Pathogenic Tissue Deposition of Mutant TTR Protein by Greater than 95% -

– Research Findings Include Rational Design of Mimetic Lipoprotein Particles (MLPs), a Novel Delivery Technology, New Data Regarding Potency of RNAi-Mediated Gene Silencing, and an Update on RNA Activation Research Efforts –

See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5099493 for the full story.

See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Affymax, Inc. (Nasdaq: AFFY), today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.Clinical Data, Inc. (NASDAQ: CLDA) today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing.Delcath Systems, Inc. (Nasdaq: DCTH) announced today the closing of its public offering of 9,775,000 shares of common stock priced to the public at $3.60 per share.CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.Depomed, Inc. (NASDAQ:DEPO) announced today that William Callahan has been promoted to vice president, Operations. Mr. Callahan joined Depomed in 2002 and most recently held the position of senior director, Operations.Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.PPD, Inc. (NASDAQ:PPDI) today announced it has signed an agreement to acquire BioDuro LLC, a drug discovery outsourcing company that provides a broad range of integrated services to biopharmaceutical companies. The acquisition will expand PPD’s drug development capabilities in China.Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children. Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), a specialty pharmaceutical company, today announced the pricing of a public offering of 5,500,000 shares of its common stock.Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today reported data from two nonclinical studies of voreloxin at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, which is being held in Boston, MA from November 15-19, 2009.Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.Tongjitang Chinese Medicines Company (NYSE: TCM) (“Tongjitang” or the “Company”), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended September 30, 2009 and the repurchase of ordinary shares in a private transaction.YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that results from a study evaluating nimotuzumab were presented today in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.

Alnylam Pharmaceuticals Inc. (ALNY) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses. Revenues for the quarter came in at $24.2 million as against $25.7 [...]

(ALNY) Alnylam Pharmaceuticals Posts Wider Loss

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Applied Nanoscience Inc. (ANI) (PINKSHEETS:APNN), a nanotechnology-based filtration company, today issued a progress report to its investors relating to progress in commercializing the disposable NanoFense™ Protective Face Mask, designed to offer superior protection against a broad spectrum of harmful virus, bacteria and fungi.Amarin Corp. (NASDAQ:AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.Adolor Corporation (Nasdaq:ADLR) announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD).Abbott (NYSE:ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.CellCyte Genetics Corporation (OTC:CCYG) announced the appointment of Dr. Douglas Cerretti as Chief Science Officer and Director of Business Development effective November 1, 2009.DuPont (NYSE:DD) and BSES Limited announced a research, development and commercialization alliance to improve productivity and use of sugarcane varieties.Edwards Lifesciences Corporation (NYSE:EW), the global leader in the science of heart valves and hemodynamic monitoring, announced The Edwards Lifesciences Fund is granting $1.8 million to 107 nonprofit organizations as part of its fifth annual grant cycle. This fund is a donor-advised fund of the Vanguard Charitable Endowment Program.Inovio Biomedical Corporation (NYSE:INO), a leader in DNA vaccine design, development and delivery, announced the company will highlight its technology at two worldwide vaccine conferences next week. Dr. David Weiner, Chair of Inovio’s Scientific Advisory Board, and Niranjan Sardesai, Senior Vice President, SVP, Research and Development will speak on Inovio’s DNA vaccine development.Inhibitex, Inc. (Nasdaq:INHX), announced Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City on Tuesday, November 17, 2009 at 1:40 p.m. Eastern Time.Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the quarter ended September 30, 2009.Medtronic, Inc. (NYSE:MDT) announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives.Mach One Corporation (OTC:MNCN), a rapidly growing, innovative, global wellness solutions company, announced it has completed the first tranche of its investment in PanTheryx, Inc., as stipulated in a recent Letter of Understanding signed in August 2009.Millipore Corporation (NYSE:MIL) a leading provider of technologies, tools and services for the global life science industry has been named “Corporate Citizen of the Year” by the New England Clean Energy Council.NeoGenomics, Inc. (OTC:NGNM) announced it will present at the Lazard Capital Markets 6th Annual Healthcare Conference being held November 17-18, 2009, at the St. Regis, New York Hotel in New York City.Nutra Pharma Corp. (OTC:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever.Nile Therapeutics, Inc. (NASDAQ:NLTX), a company focused on the development of novel therapeutics for heart failure patients, announced its third quarter financial results for 2009.For the fiscal year ending June 30th, 2009, PD-Rx (Pink Sheets: PDRX) set record sales of $26.9 million over last year's sales figures of $26.4 million, reporting a net increase in sales of $493,230.PharmAthene, Inc. (NYSE:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, reported financial and operational results for the third quarter and nine months ended September 30, 2009.Repros Therapeutics Inc. (Nasdaq:RPRX) announced it has elected Dr. Jaye Thompson to its Board of Directors, and as a member of the Board’s Audit Committee, effective immediately.Shire plc (Nasdaq:SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®.In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.ULURU Inc. (NYSE:ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, announced it has entered into definitive agreements to sell 10,714,467 shares of its common stock at a price per share of $0.14 pursuant to a registered direct offering to institutional investors, resulting in gross proceeds of approximately $1.5 million.

Alnylam Pharmaceuticals Inc. (ALNY) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses.

Revenues for the quarter came in at $24.2 million as against $25.7 million in the year-ago quarter, down 5.8%. Research and development costs increased 5% to $23.2 million primarily because of increased costs for clinical and pre-clinical programs coupled with increased R&D headcount to support Alnylam’s alliances and development programs. 
 
General and administrative expenses increased 56% to $10.7 million. The increase in general and administrative spend was primarily driven by higher professional service fees in association with business activities, primarily legal activities, coupled with increased stock based compensation expenses.
 
Alnylam exited the quarter with $453.5 million in cash, cash equivalents and marketable securities and no debt compared to $512.7 million at the end of 2008. We are comfortable with the company’s current cash position, which allays our concern about its cash burn rate. Alnylam expects to end the year with cash, cash equivalents, and marketable securities balance in excess of $430 million.
 
Alnylam Pharmaceuticals, headquartered in Cambridge, Massachusetts, focuses on developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). The company has entered into collaborations or deals with big pharmaceutical players like Novartis (NVS), Biogen Idec (BIIB), Roche and Takeda  to further develop and utilize its core technology. The partnerships with major players further validate the potential and viability of the RNAi approach. We believe the company will continue to form new alliances with leading pharmaceutical and biotech companies in future.
 
Currently, we are Neutral on Alnylam.

Read the full analyst report on "ALNY"
Read the full analyst report on "BIIB"
Read the full analyst report on "NVS"
Zacks Investment Research

Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 7 cents per share in the third quarter, which was wider than the Zacks Consensus Estimate of a net loss of 5 cents. The company had reported a net income of 2 cents in the year ago period. The wider-than-expected loss was due to lower revenues [...]

(ISIS) Isis Pharmaceuticals’ Loss Widens